Branched Chain Amino Acids for Sarcopenia in Patients Undergoing Total Knee Arthroplasty

Sponsor
Seoul National University Hospital
Study ID
NCT07634523
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Sarcopenia
  • Total Knee Arthroplasty

Eligibility Criteria

Sex
ALL
Age
40 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Livact Granule — DRUG
    Livact granules 4.15 g are administered orally, one packet three times daily after meals for 3 months after total knee arthroplasty.

Study Details

This multicenter, prospective, randomized controlled trial evaluates whether postoperative administration of branched chain amino acids affects skeletal muscle mass index and sarcopenia related functional outcomes in patients undergoing total knee arthroplasty. Participants are randomly assigned to receive Livact granules 4.15 g three times daily for 3 months after surgery or to receive standard postoperative care without branched chain amino acid administration. Skeletal muscle mass index, physical function, patient reported outcomes, laboratory findings, medication compliance, and adverse events are assessed at baseline, 5 weeks, and 15 weeks after surgery.

Key Dates

First listed
Jun 9, 2026
Start date
Feb 6, 2025
Status verified
May 2026
Primary completion
May 31, 2027
Completion
May 31, 2027

Study Design

Enrollment
140 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Branched Chain Amino Acid Group
    Participants receive Livact granules 4.15 g orally three times daily for 3 months after total knee arthroplasty, in addition to standard postoperative care.
  • No Intervention: Control Group
    Participants receive standard postoperative care without branched chain amino acid administration.

Primary Outcome Measure

Change in Skeletal Muscle Mass Index From Baseline to 15 Weeks After Surgery [ Time Frame: Baseline and 15 weeks after surgery ]

Central Contacts

Related Studies